Alba Santos1,2,3,4, David Lagares5,6,7,8. 1. Fibrosis Research Center, Massachusetts General Hospital, Boston, MA, USA. 2. Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, USA. 3. Division of Pulmonary and Critical Care, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. 4. Harvard Medical School, Boston, MA, USA. 5. Fibrosis Research Center, Massachusetts General Hospital, Boston, MA, USA. dlagares@mgh.harvard.edu. 6. Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, USA. dlagares@mgh.harvard.edu. 7. Division of Pulmonary and Critical Care, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. dlagares@mgh.harvard.edu. 8. Harvard Medical School, Boston, MA, USA. dlagares@mgh.harvard.edu.
Abstract
PURPOSE OF REVIEW: Organ fibrosis is a lethal component of scleroderma. The hallmark of scleroderma fibrosis is extensive extracellular matrix (ECM) deposition by activated myofibroblasts, specialized hyper-contractile cells that promote ECM remodeling and matrix stiffening. The purpose of this review is to discuss novel mechanistic insight into myofibroblast activation in scleroderma. RECENT FINDINGS: Matrix stiffness, traditionally viewed as an end point of organ fibrosis, is now recognized as a critical regulator of tissue fibrogenesis that hijacks the normal physiologic wound-healing program to promote organ fibrosis. Here, we discuss how matrix stiffness orchestrates fibrosis by controlling three fundamental pro-fibrotic mechanisms: (a) mechanoactivation of myofibroblasts, (b) integrin-mediated latent transforming growth factor beta 1 (TGF-β1) activation, and (c) activation of non-canonical TGF-β1 signaling pathways. We also summarize novel therapeutic targets for anti-fibrotic therapy based on the mechanobiology of scleroderma. Future research on mechanobiology of scleroderma may lead to important clinical applications such as improved diagnosis and treatment of patients with scleroderma and other fibrotic-related diseases.
PURPOSE OF REVIEW: Organ fibrosis is a lethal component of scleroderma. The hallmark of scleroderma fibrosis is extensive extracellular matrix (ECM) deposition by activated myofibroblasts, specialized hyper-contractile cells that promote ECM remodeling and matrix stiffening. The purpose of this review is to discuss novel mechanistic insight into myofibroblast activation in scleroderma. RECENT FINDINGS: Matrix stiffness, traditionally viewed as an end point of organ fibrosis, is now recognized as a critical regulator of tissue fibrogenesis that hijacks the normal physiologic wound-healing program to promote organ fibrosis. Here, we discuss how matrix stiffness orchestrates fibrosis by controlling three fundamental pro-fibrotic mechanisms: (a) mechanoactivation of myofibroblasts, (b) integrin-mediated latent transforming growth factor beta 1 (TGF-β1) activation, and (c) activation of non-canonical TGF-β1 signaling pathways. We also summarize novel therapeutic targets for anti-fibrotic therapy based on the mechanobiology of scleroderma. Future research on mechanobiology of scleroderma may lead to important clinical applications such as improved diagnosis and treatment of patients with scleroderma and other fibrotic-related diseases.
Authors: James J Tomasek; Giulio Gabbiani; Boris Hinz; Christine Chaponnier; Robert A Brown Journal: Nat Rev Mol Cell Biol Date: 2002-05 Impact factor: 94.444
Authors: Nilgun I Reed; Hyunil Jo; Chun Chen; Kazuyuki Tsujino; Thomas D Arnold; William F DeGrado; Dean Sheppard Journal: Sci Transl Med Date: 2015-05-20 Impact factor: 17.956
Authors: Laura A Johnson; Eva S Rodansky; Andrew J Haak; Scott D Larsen; Richard R Neubig; Peter D R Higgins Journal: Inflamm Bowel Dis Date: 2014-01 Impact factor: 5.325
Authors: José González-Santamaría; María Villalba; Oscar Busnadiego; Marina M López-Olañeta; Pilar Sandoval; Jessica Snabel; Manuel López-Cabrera; Janine T Erler; Roeland Hanemaaijer; Enrique Lara-Pezzi; Fernando Rodríguez-Pascual Journal: Cardiovasc Res Date: 2015-08-10 Impact factor: 10.787
Authors: Hong Jiang; Samarth Hegde; Brett L Knolhoff; Yu Zhu; John M Herndon; Melissa A Meyer; Timothy M Nywening; William G Hawkins; Irina M Shapiro; David T Weaver; Jonathan A Pachter; Andrea Wang-Gillam; David G DeNardo Journal: Nat Med Date: 2016-07-04 Impact factor: 53.440
Authors: Andrew J Haak; Enis Kostallari; Delphine Sicard; Giovanni Ligresti; Kyoung Moo Choi; Nunzia Caporarello; Dakota L Jones; Qi Tan; Jeffrey Meridew; Ana M Diaz Espinosa; Aja Aravamudhan; Jessica L Maiers; Rodney D Britt; Anja C Roden; Christina M Pabelick; Y S Prakash; Seyed Mehdi Nouraie; Xiaoyun Li; Yingze Zhang; Daniel J Kass; David Lagares; Andrew M Tager; Xaralabos Varelas; Vijay H Shah; Daniel J Tschumperlin Journal: Sci Transl Med Date: 2019-10-30 Impact factor: 17.956
Authors: Jörg H W Distler; Andrea-Hermina Györfi; Meera Ramanujam; Michael L Whitfield; Melanie Königshoff; Robert Lafyatis Journal: Nat Rev Rheumatol Date: 2019-11-11 Impact factor: 20.543